Floatz logo

BISMUTH SUBCITRATE

Non-alcoholic Fatty Liver Disease

Tehran University of Medical SciencesSmall moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
73/ 100

Competitive context

14 Active assets in the Non-alcoholic Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Sitagliptin
University Health Network, Toronto
Phase 4BB
RIFALDAZINE
University of Oulu
Phase 4B
LOBEGLITAZONE
Yonsei University
Phase 4B
Tocopherol
Zagazig University
Phase 4B
1,25-dihydroxyvitamin d
University Hospital Rijeka
Phase 4B

View all 47 →

Same molecule, other indications

BISMUTH SUBCITRATE is also rated in:

fatty liver diseaseDormant
B
Indicative ·
57 / 100
View asset →
Liver DysfunctionDormant
B
Indicative ·
57 / 100
View asset →
gastric mucosa-associated lymphoid tissue lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →